Table 3.
Patient-related parameters (p values are given for a comparison of the group of failing interventions with the successful group and for a comparison of subgroups A and B with the successful group)
| Success n = 100 |
Failure n = 100 |
p | Group A n = 20 |
p | Group B n = 80 |
p | |
|---|---|---|---|---|---|---|---|
| Nicotine abuse (%) | 22 (22.0) | 24 (24.0) | 0.876A | 6 (30.0) | 0.562A | 18 (22.5) | 1.000A |
| Coronary heart disease/myocardial infarction (%) | 25 (25.0) | 22 (22.0) | 0.739A | 7 (35.0) | 0.409A | 15 (18.8) | 0.369A |
| Atrial fibrillation (%) | 52 (52.0) | 39 (39.0) | 0.088A | 10 (50.0) | 1.000A | 29 (36.3) | 0.037A |
| Diabetes mellitus (%) | 18 (18.0) | 17 (17.0) | 1.000A | 4 (20.0) | 0.761A | 13 (16.2) | 1.000A |
| Heart failure (%) | 8 (8.0) | 14 (14.0) | 0.258A | 2 (10.0) | 0.672A | 12 (15.0) | 0.157A |
| Hyperlipoproteinemia (%) | 27 (27.0) | 27 (27.0) | 1.000A | 6 (30.0) | 0.788A | 21 (26.2) | 1.000A |
| Hypertension (%) | 74 (74.0) | 72 (72.0) | 0.874A | 16 (80.0) | 0.778A | 56 (70.0) | 0.616A |
| Chronic kidney disease (%) | 8 (8.0) | 8 (8.0) | 1.000A | 2 (10.0) | 0.672A | 7 (8.8) | 1.000A |
| Patent foramen ovale (%) | 2 (2.0) | 5 (5.0) | 0.445A | 0 (0.0) | 1.000A | 5 (6.3) | 0.244A |
| Endocarditis (%) | 1 (1.0) | 0 (0.0) | 1.000A | 0 (0.0) | 1.000A | 0 (0.0) | 1.000A |
| Peripheral arterial occlusive disease (%) | 4 (4.0) | 10 (10.0) | 0.164A | 4 (20.0) | 0.026A | 6 (7.5) | 0.343A |
| Autoimmune disease# (%) | 2 (2.0) | 4 (4.0) | 0.683A | 0 (0.0) | 1.000A | 4 (5.0) | 0.409A |
| Tumors+ (%) | 6 (6.0) | 7 (7.0) | 1.000A | 1 (5.0) | 1.000A | 6 (7.5) | 0.768A |
| Coagulation disorder~ (%) | 1 (1.0) | 6 (6.0) | 0.118A | 0 (0.0) | 1.000A | 6 (7.5) | 0.046A |
| Stroke/TIA in history (%) | 19 (19.0) | 16 (16.0) | 0.710A | 5 (25.0) | 0.547A | 11 (13.8) | 0.423A |
| Thrombosis/lung embolism in history (%) | 2 (2.0) | 4 (4.0) | 0.683A | 1 (5.0) | 0.424A | 3 (3.8) | 0.479A |
| Low molecular weight heparin (%) | 6 (6.0) | 3 (3.0) | 0.498A | 2 (10.0) | 0.619A | 1 (1.3) | 0.134A |
| Unfractionated heparin (%) | 3 (3.0) | 1 (1.0) | 0.621A | 0 (0.0) | 1.000A | 1 (1.3) | 0.630A |
| Coumarins (%) | 10 (10.0) | 9 (9.0) | 1.000A | 1 (5.0) | 0.689A | 8 (10.0) | 1.000A |
|
New oral anticoagulants (%) Dabigatran (%) Edoxaban (%) Apixaban (%) Rivaroxaban (%) |
8 (8.0) 2 (2.0) 1 (1.0) 2 (2.0) 3 (3.0) |
6 (6.0) 0 (0.0) 0 (0.0) 5 (0.0) 1 (1.0) |
0.783A 0.497A 1.000A 0.445A 0.621A |
1 (5.0) 0 (0.0) 0 (0.0) 1 (5.0) 0 (0.0) |
1.000A 1.000A 1.000A 0.424A 1.000A |
5 (6.3) 0 (0.0) 0 (0.0) 4 (5.0) 1 (1.3) |
0.776A 0.503A 1.000A 0.409A 0.630A |
| Ace-inhibitors (%) | 30 (30.0) | 27 (27.0) | 0.754A | 8 (40.0) | 0.435A | 19 (23.8) | 0.401A |
| AT1-receptor antagonists 8%) | 23 (23.0) | 19 (19.0) | 0.603A | 4 (20.0) | 1.000A | 15 (18.8) | 0.582A |
| Betablockers (%) | 61 (61.0) | 55 (55.0) | 0.474A | 12 (60.0) | 1.000A | 43 (53.8) | 0.364A |
| Diuretics (%) | 35 (35.0) | 43 (43.0) | 0.310A | 9 (45.0) | 0.450A | 34 (42.5) | 0.355A |
| Calcium channel blockers (%) | 27 (27.0) | 19 (19.0) | 0.239A | 3 (15.0) | 0.397A | 16 (20.0) | 0.296A |
| Nitrates (%) | 8 (8.0) | 1 (1.0) | 0.035A | 1 (5.0) | 1.000A | 0 (0.0) | 0.009A |
| Statins (%) | 31 (31.0) | 30 (30.0) | 1.000A | 10 (50.0) | 0.124A | 20 (25.0) | 0.409A |
| Metamizole (%) | 10 (10.0) | 9 (9.0) | 1.000A | 2 (10.0) | 1.000A | 7 (8.8) | 0.804A |
| Ibuprofen (%) | 2 (2.0) | 4 (4.0) | 0.682A | 0 (0.0) | 1.000A | 4 (5.0) | 0.409A |
| Acetylsalicylic acid (%) | 21 (21.0) | 31 (31.0) | 0.146A | 9 (45.0) | 0.044A | 22 (27.5) | 0.380A |
| Clopidogrel (%) | 4 (4.0) | 8 (8.0) | 0.373A | 3 (15.0) | 0.090A | 5 (6.3) | 0.514A |
| Thyroxine (%) | 17 (17.0) | 16 (16.0) | 1.000A | 4 (20.0) | 0.751A | 12 (15.0) | 0.839A |
| Glucocorticoids (%) | 2 (2.0) | 5 (5.0) | 0.445A | 2 (10.0) | 0.129A | 3 (3.8) | 0.657A |
| Lesion in internal carotid artery (%) | 40 (40.0) | 42 (42.0) | 0.886A | 13 (65.0) | 0.050A | 29 (36.3) | 0.646A |
| Lesion in middle cerebral artery. M1 (%) | 49 (49.0) | 39 (39.0) | 0.200A | 3 (15.0) | 0.006A | 36 (45.0) | 0.653A |
| Lesion in middle cerebral artery M2 (%) | 11 (11.0) | 19 (19.0) | 0.165A | 4 (20.0) | 0.274A | 15 (18.8) | 0.200A |
| Right hemisphere (%) | 43 (43.0) | 39 (39.0) | 0.666A | 11 (55.0) | 0.338A | 28 (35.0) | 0.287A |
| Left hemisphere (%) | 57 (57.0) | 61 (61.0) | 0.666A | 9 (45.0) | 0.338A | 52 (65.0) | 0.287A |
| Initial NIH-Stroke-Scale (M and IQR) | 15 (11–19) | 14 (10–19) | 0.578B | 14 (10–17) | 0.457A | 15 (10–20) | 0.723B |
| Intravenous thrombolysis (%) | 51 (51.0) | 35 (35.0) | 0.032A | 7 (35.0) | 0.226A | 28 (35.0) | 0.035A |
| Thrombolysis-intervention time [min] (M and IQR) | 90 (41–151) | 118 (47–161) | 0.351B | 139 (79–228) | 0.142A | 102 (46–152) | 0.652B |
| Onset-needle time [min] (M and IQR) | 90 (73–126) | 91 (77–117) | 0.413B | 95 (80–150) | 0.793B | 91 (75–132) | 0.404B |
| Onset-groin-puncture time [min] (M and IQR) | 158 (125–198) | 189 (134–261) | 0.608B | 271 (151–333) | 0.155B | 200 (140–270) | 0.973B |
| Onset-end-of-intervention Time [min] (M and IQR) | 194 (145–239) | 236 (220–301) | 0.055B | 308 (188–375) | 0.199B | 272 (202–318) | 0.085B |
| Intervention duration [min] (M and IQR) | 23 (14–36) | 50 (36–90) | 0.000B | 27.5 (23–52) | 0.665B | 58 (44–73) | 0.000B |
| Stroke of unknown onset (%) | 20 (20) | 26 (26) | 0.401A | 6 (30.0) | 0.374A | 20 (25.0) | 0.473A |
| C-reactive protein [mg/l] (M and IQR) | 4.5 (1.9–14.6) | 5.3 (2.4–15.4) | 0.342B | 6.1 (1.7–24.1) | 0.420B | 5.1 (2.5–12.1) | 0.431B |
| White blood cell count [×109/l] (X̅ ± SD) | 10.6 ± 4.2 | 10.4 ± 5.3 | 0.284B | 10.1 ± 4.3 | 0.576B | 9.2 ± 3.9 | 0.303B |
| INR (M and IQR) | 1.06 (0.99–1.14) | 1.04 (0.97–1.10) | 0.276B | 1.06 (1.01–1.11) | 0.719B | 1.03 (0.97–1.10) | 0.153B |
| aPTT [s] (M and IQR) | 24 (23–27) | 24 (22–27) | 0.639B | 25 (22–28) | 0.899B | 24 (23–27) | 0.546B |
| Platelet count [×109/l] (M and IQR) | 228 (186–274) | 223 (160–277) | 0.258B | 199 (142–276) | 0.108B | 227 (170–277) | 0.500B |
A, Fisher’s exact test; B, Mann-Whitney U test; M, median, IQR, interquartile range; X̅, mean; SD, standard deviation
#Vasculitis, Hashimoto thyroiditis, Crohn’s disease, rheumatoid arthritis, myasthenia gravis. No significant difference in any of the subcategories
+Active tumor disease: small cell lung cancer, non-small cell lung cancer, colorectal carcinoma, mammary carcinoma, non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, plasmocytoma, malignant melanoma, thyroid cancer, transitional cell carcinoma of the urinary tract, oropharyngeal squamous cell carcinoma, meningeoma, prostate cancer, cancer of unknown primary. No significant difference in any of the subcategories
~Heterozygous and homozygous G20210A-mutation, antiphospholipid syndrome, factor V Leiden mutation, protein c/s-deficiency, thrombotic thrombocytopenic purpura, paraneoplastic coagulation disorder. No significant difference in any of the subcategories